Innovation Pharmaceuticals Inc (IPIX)

[DoubleJ23]

Just got an email:
My Fellow Cellceutix Shareholders,

We are pleased to inform you that Cellceutix Chief Medical Officer Dr. Daniel Jorgensen’s presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) on our completed Phase 2b trial comparing Brilacidin to daptomycin in the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) has become public on the ECCMID website. Shareholders are encouraged to view the presentation at: http://eccmidlive.org/resources/a-randomized-double-blind-study-comparing-single-dose-and-short-course-brilacidin-to-daptomycin-in-the-treatment-of-acute-bacterial-skin-skin-structure-infections-absssi--2

We’d also like to point shareholders to an informative video created by BioCentury titled, “The Future of Cancer Therapies.” We found particularly interesting the discussion with the FDA’s Dr. Richard Pazdur and Dr. Amy McKee on the approval of the PARP inhibitor Lynparza to treat advanced ovarian cancer associated with defective BRCA genes. We are encouraged in the development of our anti-cancer drug Kevetrin by the FDA’s willingness to incentivize the regulatory processes for hard-to-treat diseases like ovarian cancer. The video is available at: http://www.biocenturytv.com/currentshows2 bcpid=4179652879001&bclid=4178277878001

Sincerely,

The Cellceutix Team